CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,974 enrolled
Drug / intervention
Sitagliptin (JANUVIA®)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01354990
NCT01354990N/ACompleted
CompareCT.gov

Sitagliptin (JANUVIA®) Post Marketing Surveillance Protocol

Merck Sharp & Dohme LLC·observational·Posted May 17, 2011·Updated Aug 27, 2015

In Brief

An observational study evaluating Sitagliptin (JANUVIA®) for Diabetes Mellitus, Type 2. Completed, enrolled 2,974 participants.

Detailed Summary

The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2011
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.1 years ago

Interventions

Sitagliptin (JANUVIA®)drug

Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.